Blueprint Medicines
Blueprint Medicines is a global biopharmaceutical company dedicated to inventing life-changing medicines by targeting the root causes of serious diseases, especially in allergy/inflammation and oncology/hematology. They leverage deep expertise in biology, innovative drug design, and robust clinical and commercial capabilities to develop and deliver transformative therapies. Their mission is to improve and extend patients' lives through scientific innovation, patient-centered approaches, and collaborations.
Industries
Nr. of Employees
large (251-1000)
Blueprint Medicines
Cambridge, Massachusetts, United States, North America
Products
Oral KIT-selective small-molecule inhibitor (avapritinib)
An approved oral small-molecule inhibitor targeting KIT and PDGFRA-driven diseases, authorized for indications including forms of systemic mastocytosis and PDGFRA-mutant gastrointestinal stromal tumors in certain regions.
Investigational next-generation KIT inhibitors (wild-type and mutant KIT programs)
Oral small-molecule development programs aimed at wild-type and mutant KIT-driven allergic and inflammatory diseases, intended for proof-of-concept and early clinical studies.
Investigational CDK2-directed therapies and targeted protein degraders
Preclinical and early clinical programs that include CDK2 inhibitors and targeted protein degraders for oncology indications such as HR+, HER2- breast cancer and CCNE1-amplified tumors.
Biomarker testing offering for diagnostic support
A clinical testing pathway to support detection of diagnostic mutations used to inform patient diagnosis and trial eligibility.
Oral KIT-selective small-molecule inhibitor (avapritinib)
An approved oral small-molecule inhibitor targeting KIT and PDGFRA-driven diseases, authorized for indications including forms of systemic mastocytosis and PDGFRA-mutant gastrointestinal stromal tumors in certain regions.
Investigational next-generation KIT inhibitors (wild-type and mutant KIT programs)
Oral small-molecule development programs aimed at wild-type and mutant KIT-driven allergic and inflammatory diseases, intended for proof-of-concept and early clinical studies.
Investigational CDK2-directed therapies and targeted protein degraders
Preclinical and early clinical programs that include CDK2 inhibitors and targeted protein degraders for oncology indications such as HR+, HER2- breast cancer and CCNE1-amplified tumors.
Biomarker testing offering for diagnostic support
A clinical testing pathway to support detection of diagnostic mutations used to inform patient diagnosis and trial eligibility.
Services
Patient support and access program
Phone- and web-based program providing patient assistance, affordability solutions and case support for eligible patients prescribed approved medicines.
Biomarker testing program (KIT D816V)
Provision of a biomarker testing pathway to detect disease-driving KIT mutations for eligible patients suspected of having systemic mastocytosis.
Clinical trial support and investigator-sponsored trial assistance
Support for clinical trial participation, investigator-sponsored trial collaboration, early-access policy and travel/reimbursement policies to broaden trial access.
Real-world evidence and HEOR services
Design and conduct of RWE studies, PRO instrument development and HEOR analyses to inform clinical development, payer communication and post-approval performance monitoring.
EHR-based algorithm development for rare-disease case-finding
Collaborative development of machine learning/NLP algorithms applied to electronic medical records to screen for patients who may benefit from targeted diagnostic workups.
Patient support and access program
Phone- and web-based program providing patient assistance, affordability solutions and case support for eligible patients prescribed approved medicines.
Biomarker testing program (KIT D816V)
Provision of a biomarker testing pathway to detect disease-driving KIT mutations for eligible patients suspected of having systemic mastocytosis.
Clinical trial support and investigator-sponsored trial assistance
Support for clinical trial participation, investigator-sponsored trial collaboration, early-access policy and travel/reimbursement policies to broaden trial access.
Real-world evidence and HEOR services
Design and conduct of RWE studies, PRO instrument development and HEOR analyses to inform clinical development, payer communication and post-approval performance monitoring.
EHR-based algorithm development for rare-disease case-finding
Collaborative development of machine learning/NLP algorithms applied to electronic medical records to screen for patients who may benefit from targeted diagnostic workups.
Expertise Areas
- Precision small-molecule drug discovery
- Targeted protein degradation research
- Mast cell biology and KIT-targeted therapeutics
- Clinical development for rare diseases
Key Technologies
- Structure-based drug design (co-crystallography)
- Molecular dynamics simulations
- Surface plasmon resonance (SPR) assays
- Small-angle X-ray scattering (SAXS)